semaglutide for people without diabetes and Cardiovascular Outcomes in Obesity FDA Clears Semaglutide For Cardiac

PMID: 28110911

Diabetes 63 , 33463358 (2014)

Belal MM, Proceedings (Baylor University Medical Center) (Vol 38, Issue 3, 2025, pp 291303)

Caldart F, de Pretis N, Luchini C, Ciccocioppo R, Frulloni L

Mounjaro and Zepbound (tirzepatide injection) While these medications arent semaglutide, theyre frequently discussed alongside GLP-1s because they activate similar hormone pathways that influence appetite, weight, and blood sugar

These include a history of pancreatitis, severe gastrointestinal conditions such as gastroparesis, gallbladder disease, and reduced kidney function, where dehydration from vomiting or diarrhea is the main concern